Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Absci Corporation
  6. Summary
    ABSI   US00091E1091

ABSCI CORPORATION

(ABSI)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/13/2021 09/14/2021 09/15/2021 09/16/2021 09/17/2021 Date
14.22(c) 14.22(c) 13.97(c) 12.64(c) 11.97(c) Last
176 613 276 211 322 230 392 860 1 909 173 Volume
+1.28% 0.00% -1.76% -9.52% -5.30% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 7,06 M - -
Net income 2021 -89,1 M - -
Net cash position 2021 276 M - -
P/E ratio 2021 -6,90x
Yield 2021 -
Sales 2022 17,9 M - -
Net income 2022 -76,5 M - -
Net cash position 2022 223 M - -
P/E ratio 2022 -13,7x
Yield 2022 -
Capitalization 1 108 M 1 108 M -
EV / Sales 2021 118x
EV / Sales 2022 49,4x
Nbr of Employees 169
Free-Float 83,0%
More Financials
Company
Absci Corporation, formerly AbSci LLC, is a synthetic biology company. The Company with its artificial intelligence (AI)-powered integrated drug creation platform enables the creation of protein-based drugs (biologics) by unifying biologic drug discovery and cell line development processes into one process. It uses synthetic biology technologies and deep learning AI to predict, identify, design, construct, screen,... 
Sector
Biotechnology & Medical Research
Calendar
09/20 | 05:00pmPresentation
More about the company
All news about ABSCI CORPORATION
09/13Absci to Participate in the BofA Securities 2021 Tech Solutions for Drug Disc..
GL
09/09SHAREHOLDER ALERT : Pomerantz Law Firm Investigates Claims On Behalf of Investor..
PR
09/08ABSCI : Q2 Loss Widens Even as Revenue Gains; Shares Plunge
MT
09/07ABSCI : Earnings Flash (ABSI) ABSCI Posts Q2 Revenue $728,000
MT
09/07ABSCI : Q2 Loss Widens, Revenue Advances
MT
09/07ABSCI : Management's Discussion and Analysis of Financial Condition and Results ..
AQ
09/07ABSCI CORP : Results of Operations and Financial Condition, Financial Statements..
AQ
09/07Absci Corporation Reports Consolidated Unaudited Financial Results for the Se..
CI
09/07ABSCI : Reports Second Quarter 2021 Financial and Operating Results
AQ
08/24ABSCI CORP : Change in Directors or Principal Officers (form 8-K)
AQ
08/24Absci Corporation Announces Resignation of Andreas Pihl as Chief Operating Of..
CI
08/16ABSCI : JPMorgan Starts Absci at Overweight with $30 Price Target
MT
08/16ABSCI : Stifel Starts Absci at Hold With $28 Price Target
MT
08/16ABSCI : Credit Suisse Starts Absci at Outperform with $40 PT, Says Clear Competi..
MT
08/16ABSCI : BofA Securities Starts Absci at Neutral With $26 Price Target
MT
More news
News in other languages on ABSCI CORPORATION
09/08La perte d'Absci au deuxième trimestre se creuse malgré la hausse du chiffre ..
09/07Earnings Flash (ABSI) ABSCI affiche un revenu de 728 000 $ au deuxième trimes..
09/07La perte d'Absci au deuxième trimestre se creuse, mais les recettes progresse..
More news
Analyst Recommendations on ABSCI CORPORATION
More recommendations
Chart ABSCI CORPORATION
Duration : Period :
Absci Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ABSCI CORPORATION
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Last Close Price 11,97 $
Average target price 29,00 $
Spread / Average Target 142%
EPS Revisions
Managers and Directors
Sean McClain Chief Executive Officer & Director
Gregory T. Schiffman Chief Financial Officer
Ivana Magovcevic-Liebisch Chairman
Matthew Weinstock Chief Technology Officer
Andreas Pihl Chief Operating Officer & Director
Sector and Competitors
1st jan.Capi. (M$)
ABSCI CORPORATION0.00%1 108
MODERNA, INC.311.65%173 588
LONZA GROUP AG32.35%60 074
IQVIA HOLDINGS INC.43.07%49 116
CELLTRION, INC.-23.26%31 904
SEAGEN INC.-10.81%28 420